McMaster University has partnered with the University of Toronto, Venture Ontario and veteran investor Genesys Capital to create a new life sciences venture capital fund, providing a major boost to Ontario life sciences startups and Canada\u2019s health innovation ecosystem.<\/p>\n
The Genesys University Seed Fund will be a vital source of early-stage capital for fledgling startups, helping to translate promising university-based commercial ideas into viable companies that address critical health challenges, improve patient care and create cutting-edge Canadian jobs. To date, the fund has received support from several backers, including McMaster, U of T, the Temerty Group, Venture Ontario and RBC, and has held a first close representing over $30 million of commitments.<\/p>\n
\u201cIt\u2019s a pivotal time for universities to contribute to Canada\u2019s prosperity,\u201d said McMaster President Susan Tighe. \u201cWith a strong foundation in bench-to-bedside research and deep collaborations across institutions, we are well positioned to translate discoveries into companies that improve health care and save lives.\u201d<\/p>\n
\u201cBuilding on the early success of the McMaster Seed Fund, this partnership with Genesys and other investors will help scale these efforts \u2014fuelling a thriving life sciences cluster and driving economic growth across our region.\u201d<\/p>\n
\u201cIf Canada is going to meet the moment in driving greater innovation, it is vital that Canadian discoveries don\u2019t stall at the lab door,\u201d said U of T president Melanie A. Woodin. \u201cCanada has no shortage of ideas or talent; what we lack is the capital to scale them. That\u2019s why the University of Toronto is proud to work with Genesys Capital on the creation of this exciting new catalyst for life sciences startups, which will enable promising research to grow into companies that improve care, create jobs, and attract investment here at home.\u201d<\/p>\n
With nearly 76,000 skilled workers in more than 2,000 firms<\/a>, Ontario enjoys one of the largest life sciences clusters in North America. However, it trails other jurisdictions, particularly in the United States, when it comes to access to early-stage investment capital.<\/p>\n The result is many of Canada\u2019s promising life sciences innovators are opting to relocate to places like Boston and Silicon Valley to get their companies off the ground.<\/p>\n The Genesys University Seed Fund addresses this critical gap. By providing early-stage life sciences companies with access to venture capital, McMaster and U of T are following similar models at American universities such as MIT, UPenn, UC Berkeley and Harvard.\u00a0\u00a0The result will be a higher number of university-affiliated life sciences startups choosing to stay and grow in Ontario, bringing innovations to benefit patients and spur economic growth.<\/p>\n \u201cOntario is home to one of the most dynamic life sciences ecosystems in North America, and access to early-stage capital is essential to maintaining this advantage,\u201d said Vic Fedeli, minister of Economic Development, Job Creation and Trade. \u201cThrough Venture Ontario, our government is proud to support an initiative that will bridge the gap from breakthroughs to commercialization by bringing together leading investors and research institutions.\u201d<\/p>\n \u201cBy helping more life sciences companies start, scale, and succeed in Ontario, we are unlocking the full power of our economy and safeguarding the long-term competitiveness of this critical sector.\u201d<\/p>\n The seed fund will have a positive long-term impact across the province by enabling Ontario to attract and retain more life sciences talent as well as generate additional investment to grow the sector \u2014 a key part of Venture Ontario\u2019s mandate.<\/p>\n \u201cVenture Ontario is proud to help anchor this early-stage life sciences fund, bridging the gap between world-class university research and the development of life sciences treatments, therapies, and devices,\u201d added Steve Romanyshyn, president and CEO of Venture Ontario.<\/p>\n \u201cBy backing local talent with vital capital, we are driving both societal benefits and strong economic returns. This initiative signals to domestic and global investors that Ontario and Canada are premier destinations for high-impact innovation.\u201d<\/p>\n The fund will be overseen and managed by Genesys Capital, one of Canada\u2019s leading life sciences venture capital firms, with more than $400 million invested over the past 25 years. Genesys Capital is an active partner in biotechnology, pharmaceuticals and medical technology startups, with 20 exits representing billions in value as a founding investor.<\/p>\n \u201cAccess to capital is the lifeblood of any healthy economy, especially in a high-tech area like the life sciences,\u201d\u00a0said Kelly\u00a0Holman,\u00a0co-founder and\u00a0managing\u00a0director of Genesys Capital.<\/p>\n \u201cGenesys Capital has been proud to support many cutting-edge health startups, including companies coming out of U of T and McMaster. This early-stage venture fund will elevate this work to exciting new heights.\u201d<\/p>\n The fund will also\u00a0build momentum from\u00a0its\u00a0success.\u00a0As limited partners,\u00a0McMaster University and\u00a0the University of Toronto\u00a0will direct returns\u00a0on their investments\u00a0to\u00a0support\u00a0further research and innovation at the two\u00a0universities. In turn, this will spur even more startup activity in a positive cycle.<\/p>\n \u201cResearchers at Ontario\u2019s world-class universities are renowned for producing some of the world\u2019s brightest life sciences discoveries that save and improve lives,\u201d said Nolan Quinn, minister of Colleges, Universities, Research Excellence and Security. \u201cThe Genesys University Seed Fund will ensure that the life sciences startups emerging from Ontario\u2019s universities have the resources they need to turn their ideas into solutions that create jobs, drive our economy, and further cement our province as a global leader in innovation.\u201d<\/p>\n McMaster University\u00a0and the University of Toronto\u00a0share a strong entrepreneurial and health sciences\u00a0track record\u00a0spurring\u00a0cutting-edge\u00a0startups such\u00a0as Fusion Pharmaceuticals, Deep Genomics,\u00a0AmacaThera,\u00a0NodeAI, Profound Medical,\u00a0Biossil,\u00a0Kapoose\u00a0Creek,\u00a0AtomVie\u00a0and many others.<\/p>\n McMaster is globally recognized for translating research into real-world impact, having supported nearly 400 startups, including Fusion Pharmaceuticals, acquired by AstraZeneca in 2024 for $2B USD<\/a> \u2014 one of the largest university-linked exits in Canadian history and a catalyst for the growth of a regional radiopharmaceutical cluster.<\/p>\n